Journal article

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group

Mohamed Amgad, Elisabeth Specht Stovgaard, Eva Balslev, Jeppe Thagaard, Weijie Chen, Sarah Dudgeon, Ashish Sharma, Jennifer K Kerner, Carsten Denkert, Yinyin Yuan, Khalid AbdulJabbar, Stephan Wienert, Peter Savas, Leonie Voorwerk, Andrew H Beck, Anant Madabhushi, Johan Hartman, Manu M Sebastian, Hugo M Horlings, Jan Hudecek Show all

npj Breast Cancer | NATURE RESEARCH | Published : 2020

Abstract

Assessment of tumor-infiltrating lymphocytes (TILs) is increasingly recognized as an integral part of the prognostic workflow in triple-negative (TNBC) and HER2-positive breast cancer, as well as many other solid tumors. This recognition has come about thanks to standardized visual reporting guidelines, which helped to reduce inter-reader variability. Now, there are ripe opportunities to employ computational methods that extract spatio-morphologic predictive features, enabling computer-aided diagnostics. We detail the benefits of computational TILs assessment, the readiness of TILs scoring for computational assessment, and outline considerations for overcoming key barriers to clinical transl..

View full abstract

Grants

Awarded by National Institutes of Health National Cancer Institute (NCI)


Awarded by Breast Cancer Research Foundation (BCRF)


Awarded by NCI


Awarded by National Center for Research Resources


Awarded by VA Merit Review Award from the United States Department of Veterans Affairs Biomedical Laboratory Research and Development Service


Awarded by DOD Prostate Cancer Idea Development Award


Awarded by DOD Lung Cancer InvestigatorInitiated Translational Research Award


Awarded by DOD Peer Reviewed Cancer Research Program


Awarded by Susan G Komen Foundation


Awarded by DHHS/NCI Cancer Center Support Grant (CCSG)


Funding Acknowledgements

L.A.D.C. is supported in part by the National Institutes of Health National Cancer Institute (NCI) grants U01CA220401 and U24CA19436201. R.S. is supported by the Breast Cancer Research Foundation (BCRF), grant No. 17-194. J.S. is supported in part by NCI grants UG3CA225021 and U24CA215109. A.M. is supported in part by NCI grants 1U24CA199374-01, R01CA202752-01A1, R01CA208236-01A1, R01 CA21657901A1, R01 CA220581-01A1, 1U01 CA239055-01, National Center for Research Resources under award number 1 C06 RR12463-01, VA Merit Review Award IBX004121A from the United States Department of Veterans Affairs Biomedical Laboratory Research and Development Service, the DOD Prostate Cancer Idea Development Award (W81XWH-15-1-0558), the DOD Lung Cancer InvestigatorInitiated Translational Research Award (W81XWH-18-1-0440), the DOD Peer Reviewed Cancer Research Program (W81XWH-16-1-0329), the Ohio Third Frontier Technology Validation Fund, the Wallace H. Coulter Foundation Program in the Department of Biomedical Engineering and the Clinical and Translational Science Award Program (CTSA) at Case Western Reserve University. S.G. is supported by Susan G Komen Foundation (CCR CCR18547966) and a Young Investigator Grant from the Breast Cancer Alliance. T.O.N. receives funding support from the Canadian Cancer Society. M.M.S. is supported by P30 CA16672 DHHS/NCI Cancer Center Support Grant (CCSG). A.S. is supported in part by NCI grants 1UG3CA225021, 1U24CA215109, and Leidos 14 x 138. This work includes contributions from, and was reviewed by, individuals at the F.D.A. This work has been approved for publication by the agency, but it does not necessarily reflect official agency policy. Certain commercial materials and equipment are identified in order to adequately specify experimental procedures. In no case does such identification imply recommendation or endorsement by the FDA, nor does it imply that the items identified are necessarily the best available for the purpose. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the US Department of Veterans Affairs, the Department of Defense, the United States Government, or other governments or entities. The following is a list of current members of the International Immuno-Oncology Working Group (TILs Working Group). Members contributed to the manuscript through discussions, including at the yearly TIL-WG meeting, and have reviewed and provided input on the manuscript. The authors alone are responsible for the views expressed in the work of the TILs Working Group and they do not necessarily represent the decisions, policy or views of their employer.